Header
Header
Article

Isatuximab in the Treatment of Multiple Myeloma: A Review and Comparison With Daratumumab


. 2022 Jan-Dec;21:15330338221106563.


doi: 10.1177/15330338221106563.

Affiliations

Item in Clipboard

Fei Shen et al.


Technol Cancer Res Treat.


2022 Jan-Dec.

Abstract

Multiple myeloma (MM) is a hematologic malignancy characterized by the proliferation of clonal plasma cells. Although advances in treatment have markedly improved survival outcomes for patients with MM, this disease is still considered incurable owing to its high incidence of relapse and refractoriness. Isatuximab is an anti-CD38 monoclonal antibody that can induce apoptosis in myeloma cells through a variety of mechanisms. Many clinical studies have demonstrated the efficacy and efficiency of isatuximab in both relapsed/refractory multiple myeloma (RRMM) and newly diagnosed multiple myeloma, leading to its approval for the treatment of adults with RRMM in combination therapies. In this review, the structure, mechanisms of action, pharmacokinetics, pharmacogenetics, and safety profile of isatuximab in MM are summarized. Additionally, isatuximab is compared with daratumumab in terms of mechanism and efficacy.


Keywords:

anti-CD38 antibody; daratumumab; isatuximab; monoclonal antibody; multiple myeloma; relapsed/refractory.



Source link

Back to top button